Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111372 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jorge Morones und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Morphology, Basic Sciences Center, Universidad Autónoma de Aguascalientes, Aguascalientes 20100, Mexico. Hauptthemen laut MEDLINE: PPAR gamma, Diabetes Mellitus, Experimental, Pioglitazone, Rats, Wistar. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Humanidades, Ciencias y Tecnologías, CONAHCYT, the Universidad Autónoma de Aguascalientes.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a globally widespread complication of diabetes mellitus (DM). Research indicates that pioglitazone and linagliptin mitigate the risk of DN by reducing inflammation, oxidative stress, and fibrosis. The role of tamsulosin in DN is less studied, but it may contribute to reducing oxidative stress and inflammatory responses. The protective effects of combining pioglitazone, linagliptin, and tamsulosin on the kidneys have scarcely been investigated. This study examines the individual and combined effects of these drugs on DN in Wistar rats. Diabetic rats were treated with tamsulosin, pioglitazone, and linagliptin for six weeks. We assessed food and water intake, estimated glomerular filtration rate (eGFR), histological markers, urea, creatinine, glucose, NF-κB, IL-1, IL-10, TGF-β, and Col-IV using immunofluorescence and qPCR. The DN group exhibited hyperglycaemia, reduced eGFR, and tissue damage. Tamsulosin and linagliptin improved eGFR, decreased urinary glucose, and repaired tissue damage. Pioglitazone and its combinations restored serum and urinary markers and reduced tissue damage. Linagliptin lowered serum creatinine and tissue injury. In conclusion, tamsulosin, linagliptin, and pioglitazone demonstrated renoprotective effects in DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Morphology, Basic Sciences Center, Universidad Autónoma de Aguascalientes, Aguascalientes 20100, Mexico.
- Department of Chemistry, Basic Sciences Center, Universidad Autónoma de Aguascalientes, Aguascalientes 20100, Mexico.
- Family Medicine Unit 8, Instituto Mexicano del Seguro Social (IMSS), Aguascalientes 20180, Mexico.
- Department of Nephrology, Regional General Hospital No. 46, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44910, Mexico.
- Department of Microbiology, Basic Sciences Center, Universidad Autónoma de Aguascalientes, Aguascalientes 20100, Mexico.
ORCID-Profile: Martín Muñoz, Manuel Ávila, Jorge Topete, Javier Ventura, Sandra Martínez
Förderung
- Consejo Nacional de Humanidades, Ciencias y Tecnologías
- CONAHCYT
- the Universidad Autónoma de Aguascalientes
- Institute of Science and Technology of the State of Aguascalientes
Zitieren
APA
Morones, J., Pérez, M., Muñoz, M., Sánchez, E., Ávila, M., Topete, J., Ventura, J., & Martínez, S. (2024). Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111372
Vancouver
Morones J, Pérez M, Muñoz M, Sánchez E, Ávila M, Topete J, et al. Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111372
BibTeX
@article{Morones2024,
author = {Morones, Jorge and Pérez, Mariana and Muñoz, Martín and Sánchez, Esperanza and Ávila, Manuel and Topete, Jorge and Ventura, Javier and Martínez, Sandra},
title = {Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111372}
}
EUVIMED